What is the recommended treatment for hematuria?

Treatment for Hematuria

The treatment of hematuria is not a single intervention but rather depends entirely on identifying and treating the underlying cause through systematic evaluation—there is no "treatment for hematuria" itself, only treatment of what's causing it. 1

Critical First Principle: Hematuria is a Symptom, Not a Disease

Hematuria requires diagnostic evaluation first, not empiric treatment. The primary goal is to identify potentially life-threatening conditions, particularly malignancy, which can be missed if evaluation is delayed or incomplete. Delays in bladder cancer diagnosis have been associated with a 34% increased risk of cancer-specific mortality 1.

Initial Evaluation Algorithm

Step 1: Confirm True Hematuria

• Confirm heme-positive dipstick results with microscopic urinalysis showing ≥3 RBCs per high-powered field before initiating any further workup 2
• Obtain detailed history including:
  • Smoking history (strongest modifiable risk factor for urothelial cancer)
  • History of gross vs. microscopic hematuria
  • Occupational/environmental exposures
  • Family history of urologic malignancies
  • Anticoagulation/antiplatelet use
  • Blood pressure and serum creatinine 1

Step 2: Risk Stratification (2025 AUA/SUFU System)

Based on the most recent 2025 AUA/SUFU guidelines 1, patients should be stratified into:

• Low/negligible risk (0%-0.4% malignancy risk)
• Intermediate risk (0.2%-3.1% malignancy risk)
• High risk (1.3%-6.3% malignancy risk)

This stratification guides the intensity and urgency of evaluation.

Step 3: Differentiate Gross vs. Microscopic Hematuria

For Gross Hematuria:

• Refer immediately for urologic evaluation, even if self-limited 2
• Cancer risk consistently >10% and can exceed 25% in referral series 2
• Painless gross hematuria has particularly strong association with malignancy
• Symptomatic gross hematuria with flank pain suggests stone disease but still requires full evaluation

For Microscopic Hematuria:

• Consider urology referral for cystoscopy and imaging in adults with confirmed microscopic hematuria in the absence of demonstrable benign cause 2
• Cancer risk ranges 0.5%-5.0% overall, but 7%-20% in higher-risk subgroups 2

Management Based on Identified Cause

If Urinary Tract Infection is Identified:

• Treat with appropriate antibiotics
• Recheck urinalysis at approximately 12 weeks to allow natural resolution of infection-related hematuria 3
• Resolution occurs in only 38% at 30 days, 50% at 60 days, and 75% at 180 days
• Earlier rechecking increases likelihood of persistent false-positive results
• If hematuria persists after 12 weeks post-treatment, proceed with full urologic evaluation 3

If Benign Prostatic Hyperplasia with Bleeding:

• Finasteride has shown 91% effectiveness in controlling gross hematuria secondary to prostatic bleeding 4
• Consider for patients with documented prostatic source

If Acute Urinary Retention from Clot:

• Manage with continuous bladder irrigation 5
• Emergency surgical intervention rarely required

Critical Management Principles:

Do NOT:

• Do not obtain urinary cytology or urine-based molecular markers (NMP22, BTA stat, ImmunoCyt, UroVysion) in initial evaluation 2
• These miss 18%-43% of bladder cancers and give false-positives in 12%-26% 2
• Do not use screening urinalysis for cancer detection in asymptomatic adults 2
• Do not accept anticoagulation/antiplatelet therapy as satisfactory explanation for hematuria 2
• Pursue full evaluation even in anticoagulated patients 2, 6

Do:

• Perform cystoscopy as primary modality for bladder cancer detection (most cancers in hematuria patients are bladder cancers, optimally detected with cystoscopy) 1
• Use upper tract imaging (CT urography) selectively based on risk stratification
• Consider concurrent nephrologic evaluation if findings suggest medical renal disease (hypertension, renal insufficiency, cellular casts, proteinuria, dysmorphic RBCs) 2

Common Pitfalls to Avoid:

1. Underuse of cystoscopy: Relying solely on imaging misses bladder cancers 1
2. Attributing hematuria to anticoagulation: This requires same evaluation as non-anticoagulated patients 2
3. Premature repeat testing after UTI: Wait 12 weeks for optimal resolution 3
4. Using urine markers in initial evaluation: Not recommended and unreliable 2
5. Failing to ask about gross hematuria history: Even single episode warrants evaluation 2

Radiation and Harm Considerations:

CT urography carries effective radiation dose of 20-30 mSv with lifetime attributable cancer risk of 4 cases per 1000 patients 2. The 2025 guidelines emphasize more selective use of CT imaging based on risk stratification to balance cancer detection against radiation exposure 1.